

Monitoring for Adverse Reactions to TB Medications

Melissa Davis, RN September 11, 2024

Introduction to TB Nurse Case Management Online September 4th – September 25th, 2024 Online Course

Melissa Davis, RN has the following disclosures to make:



 No relevant financial relationships with any commercial companies pertaining to this educational activity



Texas Department of State Health Services

Monitoring for Adverse Reactions to TB Medications

Melissa Davis, RN

TB Program Manager,

Texas Department of State Health Services, Region 11

Special Thanks to Mathew Whitson, RN, Communicable Disease Consultant, Region 8





Texas Department of State Health Services

- Describe the monitoring process for adverse drug events associated with anti-TB drugs.
- Examine the difference between side effects and drug toxicities.
- List the most common adverse effects of TB therapy.




- Obtain patient information
 - Patient's weight
 - Patient's medications
 - Patient's past medical history
- Establish a rapport with the patient
 - Determine what barriers you may encounter
- Draw baseline labs
 - CBC, CMP (with creatinine level), Glucose, HIV test





- Provide education to the patient and additional family members as needed.
 - Treatment will be for months, not days.
 - Provide educational materials on medications and side effects.
 - What are the expectations of the patient? The nurse?
- Provide notification to the patient's physicians.
 - Critical if medications interact with each other.





- Medication classes that can decrease in efficacy
 - Beta blockers
 - Anticoagulants
 - Anti-depressants
 - Anti-diabetic drugs
 - Anti-anxiety agents
 - Anti-psychotics
 - ACE inhibitors
 - HMC CoA Inhibitors (statins)
 - Hormonal Contraceptives
 - Immunosuppressants
 - Opiates
- May need dosage adjustment.





- Perform baseline toxicity screening.
 - Are signs and symptoms of toxicity present before medications administered?
 - Are baseline labs normal?
 - Vision screening
 - Red/green color discrimination
 - Visual acuity
- Ensure that the medication orders are correct.





- Medical History
- MD/RN evaluation
- Chest X-ray
- Sputum Specimen
- HIV Testing
- Toxicity assessment
 - Vision screenings
- Weight
- Labs (CBC, CMP, etc.)

	Texas Department of State Health Services										
NAME:	Clinical Assessment for Tuberculosis Medication Toxicity NAME: Ss#:										
Adverse Drug Reactio	n Assessment: Ask	all the below questions	to monitor	for medica	tion toxicit	y, noting th	at some syr	mptoms may	be more o	ommonly a	ssociated
with certain medication											
other regimens. Docum	ent <u>any</u> [+], incl. pote	ential pregnancy in wo									
			Date	Date	Date	Date	Date	Date	Date	Date	Date
Weight											
Temperature											
Blood Pressure											
Pulse											
Do you have any		symptoms now o	r since y	owr last	chinic app	pointmen	ıt?				
Abdominal pain/di											
Abnormal behavio											
Allergic reaction (
Bruises, red/purple											
Change in heart ra											
Change in urine or	utput										
Convulsions**											
Dark urine (coffee											
Ears ringing/fullne											
Eye pain/irritation	(redness, excess)	ive tears)									
Fever or chills†											
Flu-like symptoms											
Headaches (chroni											
Increased gas/ston											
Jaundice (yellow s											
Joint pain/swelling		1									
Light colored stoo	ls†										
Loss of appetite*											
Malaise/fatigue											
Memory Loss**											
Mood changes/dep											
Musculoskeletal P	am.										
Nausea/vomiting*											
Numbness/tingling											
Nervousness/Gidd Skin discoloration		55									
Skin rashes/itchins											
Sleep problems**											
Sores on lips or in											
Shortness of breat											
Teeter/Fall to Left		anding (successors)									
Umusual bleeding											
easy bruising - RI		on, mane, enc.) or									
Vertigo/dizziness/											
Visual problems/c		** - EMB_RBT									
Weakness, tiredne											
Weave/Stagger wh											
Use of over the counter drugs, ie. Tylenol products?											
Ask women about											
		Route/ Frequency	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount
											
 											
Name (Title											
Name/Title											
Interpreter Next Appt.					—	—			—	—	
TB205- Clinical Ass	essment for TB V	fedication Toxicity	Revised	8/2017 /C	ontinued	on Rever	;e)				<u> </u>



Health Services

Baseline: Prior to Starting Anti-TB meds

					Texa				of Sta				rices							
NAME	3:								D.O.B.		/		/		SS#:		/	/		
The (X) m evaluation	n Color Dis sark indicates if ≤7 plates [N] = Norn	the plat are read	e canno as norr	nal.		n all 14	plates	Client	must pass	10 of	the fire	t 11 plate	s for th	se test to	be reg	arded as	nom	nal. Refe	r for	
Ishihara Plate#		Red/G Deficie						Date	Date	Da	ite	Date	Dat	e I	Date	Date	T	Date	D	ate
1	12	12								土							\Box		土	
2	8	3							1	\perp			\perp	\Box		_	\Box		\perp	
4	29	70							+	+			+	\rightarrow		+	\dashv		+	
5	74	21							+	+		\vdash	+	\rightarrow		+	\dashv		+	
6	7	X						_	+	+		\vdash	+	\dashv		+-	\dashv		+	
7	45	X							+	+			+	\dashv		+	\dashv		+	
8	2	X							工	士			工			\perp	寸		I	
9	X	2								\perp									Τ	
10	16	X								\perp							\Box		\perp	
11	Traceable	X		- In	-					丄							\perp		\perp	
		Protan Strong	Mile		trong	Mild														
12	35	5	(3)			3 (5			\perp	\perp			\perp			\perp	\Box		I	
13	96	6	(9)			9 (6)			\top							\Box		Ι	
14	Can trace 2 lines	Purple	Purp (Rec		ted	Red (Purp	a.a.			T									T	
Results	Lines		(31,01	A.F		0.00	ne)		+	+			+	\dashv		+	\dashv		+	
Initials			\top	\neg		\top			\top	\top			\top	\neg		\top	\dashv		\top	
screen in a Results:	ruity: creen was con either one or [P]=Pass w Lenses: [both eye [F]=	Fail	[U]=	ted to th	e physic	cian im	mediatel	low-up so ly. ed: []										he ini	itial
Distance Acuity			D	ate	Ds	ite	Ds	ite	Date		Date		Date		Date	D	ate		ate	,
Right Eve			2	0/	20.	/	20	/	20/		20/		20/	-	20/	20	0/	2	0/	
Left Eye				0/	20.		20		20/	_	20/		20/		20/	20			0/	
Both Eye	1			0/	20.		20		20/		20/		20/		20/	20			0/	
Results			\Box		T		T									\perp				
Initials																				
When patie the person recorded as dB until no response is	meep Checks int is taking a responds. Re greater than response is o obtained and P] = Pass	enikacin, cord the 25 dB ir obtained I recorde	finding either or until d. If a	ps for bot ear or th 20 dB is response	th the rip e same of s reache is not h	ght and car or if d. 1f 20 card at	there dB is 40 dB,	r. Refer is a chang heard, re	to an app ge of dec cord as 2 is 40+ dB	reased 0 dB.	ely lice hearing Once n	nsed pro	fession om base	al if any dine. S	two of tart with	the four h 40 dB,	freq if he	uencies s ard decr	ere esse	
Frequenc	у	Date		Date		Date		Date		Date		Date		Dat		Dat	e	D:	ate	
Ear		R	Τ.	R	t.	R	L	R	L	R	L	R	T.	R	h.	R	т.	R		L
Lar		-	-	PC.	_								_			Ex.		-		_
			_	K							Ī	Ĺ			Ť		Ť	-		
500 Hz 1000 Hz 2000 Hz			_								Ē	Ē	Ē		Ĭ		Ť			

*** From previous page: Changes in Vision may include blind spots in field of vision, blurred vision, changes in peripheral vision

TB205- Clinical Assessment for TB Medication Toxicity - Revised 8/2017

	Texas Department									
	Tuberculosis Case and	Suspe	et Ma	mage	ment !	Plan				
Patient's Name:	Patient's Name: Initial Report Date & Source:									
Nurse Case Mana	iger:	Case	Mana	gemen	t Team					
Directions: Blank	k hoxes indicate week(s) TB service is to be provided	Досим	ent date	and in	itials of	the pen	rider in	the		
Directions: Blank boxes indicate week(s) TB service is to be provided. Document date and initials of the provider in the appropriate box when the task is completed. Document comments in progress notes.										
	Action	2	4	8	12	16	20	24	26	
	Interval:	Begin	Wks	Wks	Wks	Wks	Wks	Wks	Wks	Wks
	Date: General Consents. L-30. L-36. HIPAA. TB-209.									
Consents	interpreter form PRN; TB 409, TB 410, TB 411, etc.									
Responsibility	Assign murse case manager; establish team; document in client's record									
	Obtain medical history; document on TB-202									
	Obtain release (L-30); request previous medical records									
	MD evaluation/review; document in progress notes									
	RN evaluation									
Medical	IGRA or Mantoux skin test recorded in mm (if not previously done)									
Evaluation	Chest X-ray (PA & Lateral if less than 18 years)									\Box
	Supervised sputum for AFB smear/culture according to protocol				 susceptibility 					
	HIV testing, unless patient has knowledge of HIV+ status or has documented negative HIV test result within 14 days of TB diagnosis									
	Labs per protocol or specific order									
	Nutritional assessment									
	Drug regimen according to protocol or specific order Initiate DOT on all cases/suspects: Recommended Daily									-
	X 8 weeks, then daily or 3X/week (Mon/Wed/Fri) until									
	completion of adequate therapy; document DOT on TB- 206; other DOT dosing schedules may be ordered.									
T	Pyrazinamide X2 months and ethambutol X2 months									
Treatment	(or until susceptibilities are reported and client's organism is known to be pan sensitive)									
	Vitamin B6 (if pregnant, diabetic, at risk for peripheral neuropathy)									
	Obtain Informed Consent form TB-411 (TB-411A, if									
	Spanish speaking, only) initially and for any drugs added to regimen.									
Consultation	Obtain expert consult for drug resistant cases, complicated adult/pediatric cases or client who remains									
	symptomatic or sputum positive after 2 months' therapy; written consult in client record									
	Clinical assessment according to protocol; document									\Box
Toxicity/	(TB-205 and progress note as appropriate) Visual acuity (Sloan or Snellen) and color discrimination				\vdash				\vdash	\vdash
Clinical Assessment	(Ishihara Plates) initially and monthly if on EMB or Rifabutin; document (TB-205)									
	Hearing sweep check initially and monthly if on amikacin, capreomycin, kanamycin or streptomycin; document (TB-205)									
-	document (1D-203)									

TB 201- Case Management Plan for Outpatient Care - Revised 08/2017

Administering the medications




Texas Department of State Health Services

 Ensure that the patient answers each question about toxicity before medications are given.

Ensure that the correct dosage is given at each patient encounter.

 Ask open-ended questions in addition to the closed ended questions.



Patient monitoring



Texas Department of State Health Services

- The frequency with which you monitor the patient depends on how the patient is responding to treatment.
 - How is the patient doing clinically?
 - Are there new s/sx of toxicity?
 - How were the baseline labs?
 - What do your standing delegation orders allow you to do?
- Patient should have a toxicity screening form completed at least monthly.



Drug side effects



Texas Department of State Health Services

- Unpleasant, but usually mild
- Generally resolve during or after treatment.
- Do not usually require changes in therapy.
- Can include:
 - Gas or bloating
 - Mild nausea
 - Discoloration of body fluids (RIF)
 - Photosensitivity (RIF)
 - Rash (minor)
 - Fatigue




Drug adverse effects



Texas Department of State Health Services

14

- Change in vision
- Hepatotoxicity
- Significant GI problems (severe vomiting)
- CNS toxicity
- Neurotoxicity
- Renal toxicity
- Bleeding problems
- Rash (severe, systemic involvement)



Adverse Drug Reactions



Texas Department of State Health Services

- More serious than side effects.
- May be life threatening
- Require modification of dose/discontinuation medications.
- Must be reported to the treating physician immediately.



10/3/2024 15



1st line TB medications

- Isoniazid
 - Kills rapidly dividing TB cells.
- Rifampin
 - Kills rapidly dividing TB cells.
 - Has some effect on semi-dormant TB cells.
- Pyrazinamide
 - Kills semi-dormant TB cells.
- Ethambutol
 - Protects against developing rifampin resistance.

10/3/2024 16

Common adverse effects in 1st line medications



- Isoniazid
 - Increases liver functions
 - Watch LFTs at baseline and throughout treatment.
 - Fatigue, jaundice, abdominal pain, dark urin light stools, nausea, poor appetite
 - Can cause peripheral neuropathy
 - Numbness/tingling to hands and feet.
 - Rash




Common adverse effects in 1st line medications



Texas Department of State Health Services

- Rifampin
 - Increases liver functions
 - Watch LFTs at baseline and throughout treatment.
 - Can cause low platelet count.
 - Need baseline PLTs and monitoring for thrombocytopenia.
 - Orange discoloration of body fluids.
 - Can damage kidneys and cause decreased urine output.
 - Interacts with many other medications.
 - Get patient's medication list and review with your physician.



Common adverse effects of 1st line medications



Texas Department of State Health Services

- Pyrazinamide
 - Increases liver functions
 - Watch LFTs at baseline and throughout treatment.
 - Watch Uric Acid level and monitor for joint pain.
 - Fatigue, jaundice, abdominal pain, dark urine, light stools, nausea, poor appetite
 - Can cause GI problems (upset stomach, lack of appetite)
 - Can cause rash.



Common adverse effects in 1st line medications



Texas Department of State Health Services

- Ethambutol
 - Can cause eye damage
 - Blurred vision
 - Change in color vision
 - Monitor kidney functions to adjust dosage.
 - Can cause rash



10/3/2024 20



Fluroquinolones

Drug	Standard adult Dosing	Considerations	Side Effects				
Moxifloxacin	40mg once daily, PO or IV	Good CNS Penetration	GI upset, dizziness, hypersensitivity,				
Levofloxacin	750-1,000 mg once daily, PO or IV	Good CNS penetration; adjust dose with creatine clearance < 30; avoid caffeine, milk- based products, antacids, or mineral supplements within 2 hrs. of medication	photosensitivity, headaches, arthralgias, tendonitis, tendon rupture (rare), CNS irritability, QTc prolongation, thrush, peripheral neuropathy, elevated liver enzymes (rare hepatotoxicity with moxifloxacin)				



Texas Department of State Health Services


Vision Screening


Ishihara Testing
Snellen Eye Exam





Ishihara Test


- Designed to give quick & accurate assessment of color vision
- Most effectively done in room with adequate daylight
- Held 75 cm from the patient (approx. arm length)
- Sit & tilt plate at right angle to patient's line of vision
- Screen all plates
















Normal (S,M,L)



Deutan or Red/Green (S,L)



Protan or Red/Green (S,M)



Tritan or Blue/Yellow (M,L)



Visual Acuity

- Place Snellen Chart on wall & have patient 20 feet from chart
- Have patient cover one eye at a time to read chart, recording the visual acuity for each eye, then with both eyes uncovered
- If patient misses only one letter have them continue reading the next line
- Record the last line the patient reads accurately
- If initial screen was conducted with corrective lenses(glasses/contacts), follow-up screens must be done the same.
- Change of 1 or more lines from initial screen in either one or both eyes must be reported to physician immediately





Managing & Monitoring Visual Toxicities

- 1. Baseline & monthly visual acuity test (Snellen chart)
- 2. Baseline & monthly color discrimination test (Ishihara tests)
- 3. If change from baseline:
 - a. Hold Rx
 - b. Refer for Ophthalmologic evaluation
 - c. Permanent vision impairment if ethambutol continued

Toxicity

Stop Medication ASAP with suspicion of vision, hearing loss, hepatitis, severe rash

In most cases vision loss is irreversible

Stopping medication halts extensiveness of damage

Better to miss a few doses vs disability



Rashes/Itching



Texas Department of State Health Services

- All TB drugs can cause a rash
- If the rash is not severe, the patient may be able be treated with antihistamines or low dose prednisone.
- Assess the rash
 - Location
 - Does it itch?
 - When did it start?
 - What does it look like?
 - Has the patient tried any new products food, perfume, laundry detergent.
 - Have you ruled out other involvement?





Conclusion

- 1. Initial and ongoing assessment for medication side effects or adverse effects is crucial in maintaining a safe course of treatment for the patient.
- 2. Work with the patient and your treating physician to determine cause of side effects and how to address them.
- 3. You are the eyes and ears of the physician and the mouthpiece of the patient.



Texas Department of State
Health Services





Texas Department of State Health Services

- Heartland National TB Center website
 - http://www.heartlandntbc.org/products/ print out educational items)
- CDC TB website
 - https://www.cdc.gov/tb/default.htm
- Treatment guidelines
 - https://www.cdc.gov/tb/publications/guidelines/pdf/clin-infect-dis.-2016-nahid-cid_ciw376.pdf
- TB education resources
 - https://findtbresources.cdc.gov/

10/3/2024 31



Texas Department of State Health Services

Thank you

10/3/2024 32